Profile data is unavailable for this security.
About the company
Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.
- Revenue in PLN (TTM)213.01m
- Net income in PLN-28.31m
- Incorporated2012
- Employees568.00
- LocationCelon Pharma SAul. Ogrodowa 2A, Kielpin 05-092PolandPOL
- Phone+48 227515933
- Fax+48 227514458
- Websitehttps://celonpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Poltreg SA | 900.00k | -15.65m | 219.65m | 23.00 | -- | 2.61 | -- | 244.05 | -3.36 | -3.36 | 0.193 | 18.07 | 0.0073 | 43.39 | 0.0999 | 39,560.44 | -12.68 | -6.51 | -14.06 | -7.35 | -1,242.56 | -391.38 | -1,738.56 | -449.24 | 4.90 | -- | 0.0868 | -- | 40.04 | -- | -588.92 | -- | 214.26 | -- |
| Molecure SA | 1.31m | -18.31m | 252.54m | 111.00 | -- | 1.61 | -- | 192.99 | -1.17 | -1.17 | 0.0847 | 9.34 | 0.0085 | -- | 0.2818 | 11,788.92 | -11.94 | 2.52 | -12.47 | 2.64 | -25.76 | 97.54 | -1,398.86 | 12.84 | -- | -- | 0.0434 | -- | -18.85 | 237.24 | -19.67 | -- | -24.82 | -- |
| Mabion SA | 146.11m | 42.34m | 273.14m | 226.00 | 6.45 | 2.02 | 5.49 | 1.87 | 2.62 | 2.62 | 9.04 | 8.37 | 0.7084 | 4.59 | 8.68 | 646,495.60 | 20.53 | -7.19 | 28.38 | -16.79 | 75.66 | 58.10 | 28.98 | -14.27 | 1.93 | 25.96 | 0.1513 | -- | -7.50 | -- | 77.94 | -- | 40.86 | -- |
| Bioceltix SA | 0.00 | -12.73m | 275.44m | -- | -- | 19.35 | -- | -- | -3.45 | -3.45 | 0.00 | 3.45 | 0.00 | 170.52 | -- | -- | -112.58 | -- | -140.07 | -- | -- | -- | -- | -- | 5.96 | -- | 0.0071 | -- | -- | -- | -102.87 | -- | -- | -- |
| BIOTON SA | 184.75m | -2.63m | 299.67m | 358.00 | -- | 0.4983 | 9.16 | 1.62 | -0.0306 | -0.0306 | 2.15 | 7.00 | 0.2291 | 1.00 | 6.74 | 516,050.30 | -0.3261 | -1.99 | -0.3999 | -2.47 | 34.77 | 45.33 | -1.42 | -8.61 | 0.184 | 1.16 | 0.0933 | -- | -22.10 | -5.51 | 60.10 | -38.69 | 0.3284 | -- |
| Synthaverse SA | 60.51m | 3.62m | 324.34m | 239.00 | 96.37 | 3.12 | 31.66 | 5.36 | 0.0516 | 0.0516 | 0.8605 | 1.59 | 0.2601 | 1.67 | 3.18 | 253,192.50 | 1.56 | 3.53 | 1.83 | 4.32 | 60.39 | 55.62 | 5.98 | 9.59 | 0.8723 | 3.32 | 0.4038 | -- | 16.32 | 12.66 | -21.76 | -- | 111.77 | -- |
| Captor Therapeutics SA | 13.20m | -70.58m | 331.73m | 104.00 | -- | 5.28 | -- | 25.13 | -16.42 | -16.42 | 3.04 | 14.90 | 0.1256 | -- | 3.59 | 126,932.70 | -67.13 | -- | -82.96 | -- | 52.28 | -- | -534.69 | -- | -- | -- | 0.0518 | -- | 44.15 | -- | -96.65 | -- | -- | -- |
| Scope Fluidics SA | 516.00k | -18.79m | 459.05m | 40.00 | -- | 5.67 | -- | 889.63 | -6.89 | -6.89 | 0.1893 | 29.69 | 0.0023 | 2.73 | 0.1827 | 12,900.00 | -8.39 | 52.74 | -8.61 | 57.32 | -265.89 | -420.87 | -3,640.50 | 30,134.78 | 14.60 | -- | 0.0289 | -- | 27.72 | -- | -105.76 | -- | 89.99 | -- |
| Celon Pharma SA | 213.01m | -28.31m | 800.57m | 568.00 | -- | 1.87 | 28.98 | 3.76 | -0.5545 | -0.5545 | 4.17 | 8.40 | 0.364 | 1.82 | 7.08 | -- | -4.84 | -2.24 | -5.76 | -2.57 | 71.09 | 70.71 | -13.29 | -7.79 | 1.83 | -- | 0.0546 | -- | 11.29 | 11.57 | 28.40 | -- | -13.42 | -- |
| Ryvu Therapeutics SA | 55.61m | -93.91m | 1.23bn | 230.00 | -- | 6.27 | -- | 22.04 | -4.10 | -4.10 | 2.42 | 8.45 | 0.1302 | 12.39 | 4.99 | 241,760.90 | -21.99 | -21.88 | -24.87 | -25.20 | 56.80 | -6.28 | -168.89 | -284.20 | 4.71 | -- | 0.1193 | -- | 20.32 | -9.50 | -9.94 | -- | 53.71 | -- |
| Selvita SA | 337.26m | 65.30m | 1.23bn | 387.00 | 18.86 | 3.76 | 10.92 | 3.65 | 3.56 | 3.56 | 18.37 | 17.83 | 0.553 | 9.29 | 4.70 | 398,178.30 | 10.71 | -- | 12.99 | -- | 79.66 | -- | 19.36 | -- | 1.41 | 11.34 | 0.4063 | -- | -3.48 | -- | 130.55 | -- | -- | -- |
Data as of May 28 2024. Currency figures normalised to Celon Pharma SA's reporting currency: Polish New Zloty PLN
13.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Generali PTE SAas of 21 Jul 2023 | 4.03m | 7.90% |
| Vienna PTE SA Vienna Insurance Groupas of 31 Dec 2021 | 1.30m | 2.54% |
| Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SAas of 30 Jun 2023 | 509.12k | 1.00% |
| Pekao TFI SAas of 30 Jun 2023 | 341.50k | 0.67% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 239.01k | 0.47% |
| PKO TFI SAas of 31 Oct 2023 | 133.91k | 0.26% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 104.59k | 0.21% |
| Investors TFI SAas of 31 Dec 2022 | 27.00k | 0.05% |
| Millennium TFI SAas of 31 Dec 2023 | 25.65k | 0.05% |
| SSgA Funds Management, Inc.as of 09 May 2024 | 3.46k | 0.01% |
More ▼
Data from 31 Dec 2021 - 31 Mar 2024Source: FactSet Research Systems Inc.
